ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada, supplying therapy to patients suffering with primary headache disorders.
“We are delighted to partner with RSK Medical as we look to expand the geographical coverage of our nVNS therapy amongst patients suffering with migraine and cluster headache,” said Iain Strickland, Vice President of European Operations. “RSK is an experienced medical device supplier and we warmly welcome Scott Kadwell and the RSK Medical team into our network of select distribution partners. We look forward to supporting RSK Medical in their market access activities and in our common goal of providing Canadian clinicians and patients with our proven therapeutic medical device, gammaCore Sapphire.”
“RSK Medical Inc. is excited to partner with electroCore to provide a personalized medicine approach to Canadian patients to address an unmet clinical need for primary headache disorders,” said Scott Kadwell, President of RSK Medical.
The gammaCore Sapphire system will be released upon receiving regulatory approval in Canada, anticipated in the next few months.